The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2021 | Clinical features and outcomes in patients with EFL
Annarita Conconi, MD, Ospedale degli Infermi, Biella, Italy, discusses the findings from IELSG30, a retrospective, multicenter survey of patients with primary extranodal follicular lymphoma (EFL) which aimed to define clinical features and outcomes in patients. The study included patients from 19 different countries and the most common types of EFL found were cutaneous and gastrointestinal lymphomas, with gastrointestinal lymphomas primarily located in the duodenum. Patients with cutaneous lymphomas had the best overall survival and patients with gastrointestinal lymphomas had intermediate outcomes compared to cutaneous lymphomas. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
